Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Eli Lilly and Company
LLY
$1,351.12
Name : Eli Lilly and Company
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $1,203,503,366,144.00
EPSttm : 30.81
finviz dynamic chart for LLY
Eli Lilly and Company
$1,351.12
2.29%
$31.63
LLY — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.85

Margin Of Safety %

-9

Put/Call OI Ratio

1.39

EPS Next Q Diff

3.46

EPS Last/This Y

11.26

EPS This/Next Y

15.32

Price

1351.12

Target Price

1507.96

Analyst Recom

1.59

Performance Q

7.63

Upside

-21.2%

Beta

0.41

Ticker: LLY




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-21LLY1272.21.191.51330939
2026-10-22LLY1307.261.200.81336254
2026-10-23LLY1273.751.201.17343489
2026-10-26LLY1279.671.231.04304267
2026-10-27LLY1282.041.251.76310957
2026-10-28LLY1289.431.261.68315431
2026-10-29LLY13731.290.95329225
2026-10-30LLY1417.241.311.13349457
2026-11-02LLY1412.251.341.60333687
2026-11-03LLY1409.241.371.74349378
2026-11-04LLY1417.891.401.78360588
2026-11-05LLY1367.371.421.65368726
2026-11-06LLY13531.441.27375493
2026-11-09LLY1411.931.341.07341370
2026-11-10LLY1432.141.361.71357537
2026-11-11LLY1438.171.381.52368535
2026-11-12LLY1430.731.390.96374827
2026-11-13LLY1444.81.450.87378114
2026-11-16LLY1433.791.390.69345067
2026-11-17LLY1414.761.390.91352095
2026-11-18LLY1381.481.391.10356515
2026-11-19LLY1349.661.391.17362204
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-21LLY1284.881.314200.335.02
2026-10-22LLY1306.741.313822.734.90
2026-10-23LLY1274.221.311163.034.90
2026-10-26LLY1279.57-5.012646.834.59
2026-10-27LLY1282.03-5.012675.834.59
2026-10-28LLY1289.42-5.012856.334.59
2026-10-29LLY1372.99-5.915860.134.46
2026-10-30LLY1413.35-5.914013.834.46
2026-11-02LLY1411.7547.47650.135.08
2026-11-03LLY1409.3947.49193.235.17
2026-11-04LLY1418.0747.49812.435.17
2026-11-05LLY1367.2747.47633.035.35
2026-11-06LLY1350.0047.49205.935.35
2026-11-09LLY1412.5047.412022.335.35
2026-11-10LLY1433.0448.910549.035.35
2026-11-11LLY1437.7948.99969.735.35
2026-11-12LLY1430.0848.99507.035.35
2026-11-13LLY1444.8048.910410.435.35
2026-11-16LLY1435.0148.99422.435.35
2026-11-17LLY1415.3848.89176.435.39
2026-11-18LLY1381.1848.88502.735.39
2026-11-19LLY1351.1249.28577.135.47
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-21LLY-0.030.030.83
2026-10-22LLY-0.030.030.83
2026-10-23LLY-0.030.030.83
2026-10-26LLY-0.030.260.83
2026-10-27LLY-0.030.260.82
2026-10-28LLY-0.030.260.82
2026-10-29LLY-0.030.260.82
2026-10-30LLY-0.030.260.82
2026-11-02LLY-0.030.260.82
2026-11-03LLY-0.030.260.82
2026-11-05LLY-0.040.260.82
2026-11-06LLY-0.040.260.82
2026-11-09LLY-0.020.080.82
2026-11-10LLY-0.020.080.82
2026-11-11LLY-0.020.080.85
2026-11-12LLY-0.020.080.85
2026-11-13LLY-0.020.080.85
2026-11-16LLY-0.020.040.85
2026-11-17LLY-0.020.040.85
2026-11-18LLY-0.020.040.85
2026-11-19LLY-0.020.040.85
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

7.48

Avg. EPS Est. Current Quarter

11.25

Avg. EPS Est. Next Quarter

10.94

Insider Transactions

-0.02

Institutional Transactions

0.04

Beta

0.41

Average Sales Estimate Current Quarter

24697

Average Sales Estimate Next Quarter

23549

Fair Value

1228.43

Quality Score

80

Growth Score

100

Sentiment Score

58

Actual DrawDown %

8.4

Max Drawdown 5-Year %

-34.5

Target Price

1507.96

P/E

44.39

Forward P/E

26.66

PEG

0.79

P/S

14.7

P/B

31.58

P/Free Cash Flow

64.65

EPS

30.44

Average EPS Est. Cur. Y​

35.47

EPS Next Y. (Est.)

50.8

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

31.9

Relative Volume

1.18

Return on Equity vs Sector %

41.9

Return on Equity vs Industry %

33.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.58

EBIT Estimation

8577.1
◆ LLY Healthcare
$1,351.20
📉
Swing / Pullback
Buy the dip on strong trends
31 /100
WEAK
Trend
2/20
Pullback
9/25
Volume
4/15
Valuation
10/20
TP/AR
4/10
Options
2/10
RSI
50.2
Range 1M
44.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
48 /100
WEAK
Momentum
4/25
Growth
25/30
Estimates
10/20
Inst/Vol
6/15
Options
3/10
EPS Yr
46.5%
EPS NY
42.9%
52W%
80.7%
💎
Long-Term Value
Quality companies, undervalued
58 /100
WATCH
🟡 HOLD +15.4% upside
Quality
24/30
Valuation
7/30
Growth
23/25
Stability
3/10
LT Trend
1/5
Upside
+15.4%
Quality
80
MoS
-9%
LLY — P/E HistoricalDrug Manufacturers - General
Eli Lilly and Company
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 50000
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
LLY

Latest News

—
Caricamento notizie per LLY…
stock quote shares LLY – Eli Lilly and Company Stock Price stock today
news today LLY – Eli Lilly and Company stock forecast ,stock prediction 2023 2024 2025
marketwatch LLY – Eli Lilly and Company yahoo finance google finance
stock history LLY – Eli Lilly and Company invest stock market
stock prices LLY premarket after hours
ticker LLY fair value insiders trading